1-(4-(2-(2,4-dimethylphenylsulfanyl)phenyl)piperazin-1-yl)ethanone

ID: ALA5287056

Max Phase: Preclinical

Molecular Formula: C20H24N2OS

Molecular Weight: 340.49

Names and Identifiers

Canonical SMILES:  CC(=O)N1CCN(c2ccccc2Sc2ccc(C)cc2C)CC1

Standard InChI:  InChI=1S/C20H24N2OS/c1-15-8-9-19(16(2)14-15)24-20-7-5-4-6-18(20)22-12-10-21(11-13-22)17(3)23/h4-9,14H,10-13H2,1-3H3

Standard InChI Key:  RTOYXVAUQYVQHB-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 26  0  0  0  0  0  0  0  0999 V2000
    1.0733   -0.2035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7879    0.2086    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4998   -0.2031    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.4998   -1.0284    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.7897   -1.4402    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0733   -1.0321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3587   -1.4446    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    0.3587   -2.2698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3559   -2.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0705   -2.2698    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0705   -1.4446    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3559   -1.0321    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7851   -2.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.7851   -3.5076    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    0.3587    0.2089    0.0000 S   0  0  0  0  0  0  0  0  0  0  0  0
    0.3587    1.0342    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3558    1.4469    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.3550    2.2696    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3597    2.6824    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0716    2.2732    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.0763    1.4485    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.3597    3.5076    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.0705    1.0344    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.4998   -2.2698    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  2  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  1  6  1  0
  7  6  1  0
  7  8  1  0
  9  8  1  0
 10  9  1  0
 11 10  1  0
 12 11  1  0
  7 12  1  0
 10 13  1  0
 13 14  2  0
  1 15  1  0
 15 16  1  0
 17 16  2  0
 18 17  1  0
 19 18  2  0
 20 19  1  0
 21 20  2  0
 16 21  1  0
 19 22  1  0
 17 23  1  0
 13 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA5287056

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 340.49

Molecular Weight (Monoisotopic): 340.1609

AlogP: 4.12

#Rotatable Bonds: 3

Polar Surface Area: 23.55

Molecular Species: NEUTRAL

HBA: 3

HBD: ┄

#RO5 Violations: ┄

HBA (Lipinski): 3

HBD (Lipinski): ┄

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 1.76

CX LogP: 4.37

CX LogD: 4.37

Aromatic Rings: 2

Heavy Atoms: 24

QED Weighted: 0.84

Np Likeness Score: -1.34

References

1. Talmon M, Chaudhari RD, Suryavanshi H, Chowdhury N, Quaregna M, Pin A, Bagchi A, Biswas G, Fresu LG..  (2020)  Design, synthesis and biological evaluation of vortioxetine derivatives as new COX-1/2 inhibitors in human monocytes.,  28  (23.0): [PMID:32992247] [10.1016/j.bmc.2020.115760]

Source

Source(1):

• Scientific Literature